Compare CMND & GITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMND | GITS |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Canada | South Korea |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 7.6M |
| IPO Year | 2021 | N/A |
| Metric | CMND | GITS |
|---|---|---|
| Price | $0.91 | $2.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 64.2K | ★ 115.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.66 |
| 52 Week High | $3.25 | $7.09 |
| Indicator | CMND | GITS |
|---|---|---|
| Relative Strength Index (RSI) | 29.70 | 53.84 |
| Support Level | $0.80 | $2.13 |
| Resistance Level | $1.07 | $3.28 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 10.59 | 43.27 |
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.